Novavax (NVAX) Misses Q2 EPS by $1.12
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $9.52 +5.78%
Revenue Growth %: -78.2%
Financial Fact:
Research and development: 52.98M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: -78.2%
Financial Fact:
Research and development: 52.98M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q2 EPS of ($4.75), $1.12 worse than the analyst estimate of ($3.63). Revenue for the quarter came in at $298 million versus the consensus estimate of $387.87 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
- Bristow Group to acquire Berry Aviation for $105 million
- UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
